Impact of telomere length on survival in classic and variant hairy cell leukemia

被引:8
|
作者
Arons, Evgeny [1 ]
Zhou, Hong [1 ]
Edelman, Daniel C. [2 ]
Gomez, Allison [2 ]
Steinberg, Seth M. [3 ]
Petersen, David [2 ]
Wang, Yonghong [2 ]
Meltzer, Paul S. [2 ]
Kreitman, Robert J. [1 ]
机构
[1] NCI, Mol Biol Lab, NIH, Bethesda, MD 20892 USA
[2] NCI, Canc Genet Branch, NIH, Bethesda, MD 20892 USA
[3] NCI, Biostat & Data Management Sect, Off Clin Director, Ctr Canc Res,NIH, Bethesda, MD 20892 USA
关键词
Telomere; Hairy cell leukemia; Molecular marker; Chromosomes; DNA damage; CHRONIC LYMPHOCYTIC-LEUKEMIA; LYMPHOPROLIFERATIVE DISORDERS; MYELOID-LEUKEMIA; FOLLOW-UP; DIAGNOSIS; CLADRIBINE; DYSFUNCTION; MUTATIONS; HISTOPATHOGENESIS; INSTABILITY;
D O I
10.1016/j.leukres.2015.09.015
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Telomeres, which protect the ends of chromosomes, are shortened in several hematologic malignancies, often with adverse prognostic implications, but their effect on prognosis of classic and variant hairy cell leukemia (HCL and HCLv) has not been reported. HCL/HCLv genomic DNA from 46 patients was studied by PCR to determine the ratio of telomere to single copy gene number (T/S). T/S was unrelated to diagnosis of HCL or HCLv (p = 0.27), but shorter T/S was associated with unmutated immunoglobulin rearrangements (p = 0.033) and age above the median at diagnosis (p = 0.017). Low T/S was associated with shorter overall survival from diagnosis (OS), particularly T/S <0.655 (p = 0.0064, adjusted p = 0.019). Shorter OS was also associated with presence of unmutated (p <0.0001) or IGHV4-34+ (p <0.0001) rearrangements, or increasing age (p = 0.0002). Multivariable analysis with Cox modeling showed that short T/S along with either unmutated or IGHV4-34+ rearrangements remained associated with reduced OS (p = 0.0071, p = 0.0024, respectively) after age adjustment. While T/S is relatively long in HCL and the disease usually indolent with excellent survival, shortened telomeres in HCL/HCLv are associated with decreased survival. Shortened T/S could represent a risk factor needing further investigation/intervention to determine if non-chemotherapy treatment options, in addition to or instead of chemotherapy, might be particularly useful. Published by Elsevier Ltd.
引用
收藏
页码:1360 / 1366
页数:7
相关论文
共 50 条
  • [1] Molecular Characteristic of Variant and Classic Hairy Cell Leukemia.
    Arons, Evgeny
    Suntum, Tara
    Sunshine, Joel
    Orthwein, Anna
    Margulies, Inger
    Stetler-Stevenson, Maryalice
    Kreitman, Robert
    BLOOD, 2008, 112 (11) : 389 - 389
  • [2] Molecular distinctions between variant and classic hairy cell leukemia
    Arons, E.
    Suntum, T.
    Sunshine, J.
    Orthwein, A.
    Margulies, I.
    Stetler-Stevenson, M.
    Kreitman, R. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [3] COVID-19 in patients with classic and variant hairy cell leukemia
    Kreitman, Robert J.
    Yu, Theresa
    James, Lacey
    Feurtado, Julie
    Eager, Holly
    Ortiz, Olena Sierra
    Gould, Mory
    Mauter, Jack
    Zhou, Hong
    Burbelo, Peter D.
    Cohen, Jeffrey I.
    Wang, Hao-Wei
    Yuan, Constance M.
    Arons, Evgeny
    BLOOD ADVANCES, 2023, 7 (23) : 7161 - 7168
  • [4] Phase 2 study of ibrutinib in classic and variant hairy cell leukemia
    Rogers, Kerry A.
    Andritsos, Leslie A.
    Wei, Lai
    McLaughlin, Eric M.
    Ruppert, Amy S.
    Anghelina, Mirela
    Blachly, James S.
    Call, Timothy
    Chihara, Dai
    Dauki, Anees
    Guo, Ling
    Ivy, S. Percy
    James, Lacey R.
    Jones, Daniel
    Kreitman, Robert J.
    Lozanski, Gerard
    Lucas, David M.
    Ngankeu, Apollinaire
    Phelps, Mitch
    Ravandi, Farhad
    Schiffer, Charles A.
    Carson, William E., III
    Jones, Jeffrey A.
    Grever, Michael R.
    BLOOD, 2021, 137 (25) : 3473 - 3483
  • [5] Hairy Cell Leukemia Variant
    Ashangari, Chandralekha
    Cheruku, Divya
    Tumula, Praveen K.
    BLOOD, 2018, 132
  • [6] The Biology of Classic Hairy Cell Leukemia
    Bohn, Jan-Paul
    Salcher, Stefan
    Pircher, Andreas
    Untergasser, Gerold
    Wolf, Dominik
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (15)
  • [7] Current treatment options in hairy cell leukemia and hairy cell leukemia variant
    Robak, Tadeusz
    CANCER TREATMENT REVIEWS, 2006, 32 (05) : 365 - 376
  • [8] A Unique Hairy Cell Leukemia Variant
    Jian, Charles
    Hsia, Cyrus C.
    CASE REPORTS IN ONCOLOGY, 2016, 9 (02): : 312 - 316
  • [9] Variant form of hairy cell leukemia
    Wiber, Margaux
    Maitre, Elsa
    Cornet, Edouard
    Salaun, Veronique
    Naguib, Dina
    Troussard, Xavier
    CLINICAL CASE REPORTS, 2019, 7 (06): : 1161 - 1166
  • [10] Management of hairy cell leukemia variant
    Robak, Tadeusz
    LEUKEMIA & LYMPHOMA, 2011, 52 : 53 - 56